Pfizer | PFE - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 4.73B 1.08B 2026-03
Abbott USD 1.85B 399M 2026-03
ALKERMES USD -48.28M 37.33M 2026-03
Amgen USD 3.83B 130M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Bayer EUR 3.53B 2.42B 2026-03
Biogen USD 514.3M 128.8M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Coherus Biosciences USD -39.08M 3.65M 2025-12
Drreddys Laboratories INR 14.33B 2.51B 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.29B 856M 2026-03
Glaxosmithkline GBP 2.3B 1.46B 2025-12
J&J USD 6.62B 1.03B 2026-03
Medtronic USD 2.09B 354M 2026-03
Merck USD -1.88B 8.12B 2026-03
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novartis USD 4.24B 171M 2026-03
Novartis USD 4.06B 521M 2025-12
Pacira USD 4.62M 1.43M 2026-03
Perrigo USD 33.6M 50.8M 2026-03
Pfizer USD 4.99B 340M 2026-03
Phibro Animal Health USD 54.99M 2.36M 2025-12
Prestige Brands USD 75.49M 7M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.94B 239M 2026-03
Sanofi EUR 1.5B 2.29B 2025-12
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03
Zoetis USD 865M 30M 2026-03